LYON, France--(BUSINESS WIRE)--Flamel Technologies (NASD:FLML) today announced that it has entered into a new Micropump license agreement for a combination product with a new partner and will begin formulation work immediately. Flamel also has entered into an additional feasibility agreement involving its Medusa platform with an existing partner and work has commenced. Flamel Technologies is engaged in 17 partnered projects and is working with seven of the top-twenty pharmaceutical companies in the world, including a continuing research collaboration with Pfizer Inc. (NYSE: PFE).
